Mila and Sorintellis Announce a Partnership to Optimize Complex Decision-Making Processes in Clinical Drug Development

The Mila logo and the Sorintellis logo.

MONTREAL, July 4, 2024 — Mila - Quebec Artificial Intelligence Institute is pleased to announce a partnership with Sorintellis, a Montreal-based AI company whose mission is to innovate pharmaceutical portfolio management using a data-driven approach and artificial intelligence (AI) technologies. 

Sorintellis specializes in the development of AI-powered decision support systems for the strategic management of pharmaceutical portfolios, as well as the effective planning and efficient conduct of clinical trials. The collaboration between Mila and Sorintellis represents a significant step in the field of clinical drug development, where AI has enormous potential for overcoming the many challenges involved.

“At Sorintellis, we believe that AI offers the potential to overcome the major challenges facing the innovative pharmaceutical industry, and in this case, the plurality and multi-dimensionality of risk in clinical drug development and at the highest level, the optimization of the complex decision-making processes associated with pharmaceutical portfolio management. This partnership with Mila consolidates our development strategy, opening new horizons and fostering the networking of the strengths of our AI ecosystem, which is essential for the development of innovative AI solutions to meet these challenges, and thus promote the rapid accessibility to patients of medicines with high therapeutic value, while greatly optimizing commercial value” emphasizes Emmanuel Piffo, founder and CEO  of Sorintellis. 

The collaboration between Mila and Sorintellis aims to foster the intersection of AI and clinical drug development, encouraging the creation of innovative solutions to efficiently streamline clinical drug development and increase pharmaceutical pipeline productivity. This partnership paves the way for further advances in clinical drug development and pharmaceutical portfolio management.

“Mila is pleased to welcome to Sorintellis to our community of partners. We believe in the pivotal role of AI in pioneering drug discovery and clinical trials, and by combining Sorintellis’ strategic pharmaceutical management services with Mila’s academic caliber, we look forward to working towards our shared objective of societal benefit through impactful innovation.” said Stéphane Létourneau, Executive Vice-President of Mila.

About Sorintellis

Sorintellis is a Montreal-based company specializing in artificial intelligence solutions for the pharmaceutical sector. Sorintellis was founded in March 2022 with the mission to provide contract research organizations (CROs), pharmaceutical companies and life science hedge funds with decision support systems applicable in complex decision-making processes for pharmaceutical portfolio management, as well as in the planning and conduct of clinical trials. 

Following the successful development of the proof-of-concept (PoC) of a platform for a priori estimation of the evolution of clinical trial success based on machine learning, Sorintellis is pursuing its ambition to offer, on the one hand, a platform powered by explainable AI to analyze clinical trial success and interpret risk factors, enabling the effective planning and efficient conduct of clinical trials, and on the other hand, a decision support system to support complex decision-making processes in pharmaceutical portfolio management. 

At Sorintellis, we recognize that the challenges inherent in drug development are multi-faceted, multi-dimensional and complex, and go well beyond the pharmacological efficacy and safety of the molecule to include strategic, regulatory, operational, and financial decisions to ensure commercial success. Our collaborative development approach, fueled by the pooling of pharmaceutical players and the AI strengths of our ecosystem, underpins our commitment to fostering R&D productivity, mitigating risk, maximizing return on investment and, ultimately, accelerating patient access to innovative therapies.

For more information, visit or join us at:

About Mila

Founded by Professor Yoshua Bengio of the University of Montreal, Mila is the world’s largest academic research center for deep learning, bringing together over 1,200 specialized researchers in machine learning. Based in Montreal and funded in part by the Government of Canada through the Pan-Canadian AI Strategy, Mila's mission is to be a global center for scientific advancements that inspire innovation and the growth of AI for the benefit of all. Mila is a globally recognized non-profit organization for its significant contributions to deep learning, especially in the fields of language modeling, automatic translation, object recognition, and generative models. For more information, visit